Scotia's hopes for magic bullet
The Investment Column
Wednesday 11 September 1996
Yesterday, the group was claiming that its pancreatic cancer drug, codenamed EF13, would soon outshine even Marimastat, the British Biotech anti-cancer treatment that set the sector alight last November. David Horrobin, the driving force behind Scotia, suggested EF13 could be cleared for sale in under two years and might cover a wider range of cancers. But those claims pale beside the qualities attributed to Foscan, its "magic bullet" drug which destroys cancerous cells in association with lasers. Mr Horrobin believes this could be "possibly one of the most exciting drugs, not just for Scotia but for the whole pharmaceutical industry over the next few years".
Even so, the City will remain sceptical about both drugs until more solid phase III trial results emerge and there are question marks aplenty elsewhere. Some seven months after Pharmacia & Upjohn pulled out, the group still has to find a partner to distribute Tarabetic, the diabetic treatment which should be Scotia's first major drug to hit the market early next year.
Meantime, its long-standing businesses selling treatments based on evening primrose oil and lipid technology are struggling, as the 12 per cent dip in first-half turnover shows. Losses deepened by 31 per cent to pounds 7.03m in the six months to June. At the current rate of burn, Scotia's net cash of pounds 39.3m will be used up in about 18 months.
Even after yesterday's 42p fall to 691.5p, the shares, which capitalise Scotia at pounds 532m, look high enough for now.
- 1 Benedict Cumberbatch says Hollywood is better for black British actors
- 2 Man who held up 'hire me' sign at Waterloo station returns a year later with 'I'm hiring' sign
Rowan Atkinson to sell £10 million McLaren 'supercar' he crashed into a tree and a lamppost
UK weather: Snow to fall in the coming week with sub-zero temperatures to last until early February
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
US blames Russia after rocket attacks in Ukraine kill at least 30
Warriors in ancient Iraq suffered Post-Traumatic Stress Disorder more than 3,000 years ago, say researchers
Nigel Farage: NHS might have to be replaced by private health insurance
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
French court convicts three over homophobic tweets, in case hailed as a 'significant victory' by LGBT rights campaigners
George Galloway condemns 'racist, Islamophobic, hypocritical rag' Charlie Hebdo at freedom of speech rally
British Muslim school children suffering a backlash of abuse following Paris attacks
Islamic history is full of free thinkers - but recent attempts to suppress critical thought are verging on the absurd
iJobs Money & Business
£30000 - £32000 per annum + benefits : Ashdown Group: A highly successful, int...
£18000 - £20000 per annum: Recruitment Genius: This rapidly expanding business...
Negotiable: Recruitment Genius: A Tax Assistant is required to join a leading ...
£16000 - £25000 per annum: Recruitment Genius: This is an exciting opportunity...